{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:32:16Z","timestamp":1787841136500,"version":"build-2784847793"},"reference-count":263,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["Ldyyyn2021\\u201030"],"award-info":[{"award-number":["Ldyyyn2021\\u201030"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["17JR5RA272"],"award-info":[{"award-number":["17JR5RA272"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004775","name":"Natural Science Foundation of Gansu Province","doi-asserted-by":"publisher","award":["22JR5RA923"],"award-info":[{"award-number":["22JR5RA923"]}],"id":[{"id":"10.13039\/501100004775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bbcan.2025.189459","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:32:46Z","timestamp":1758767566000},"page":"189459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy"],"prefix":"10.1016","volume":"1880","author":[{"given":"Tingting","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengtong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-xun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2025.189459_bb0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nature07943","article-title":"The cancer genome","volume":"458","author":"Stratton","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189459_bb0010","first-page":"271","article-title":"The metabolic landscape of RAS-driven cancers from biology to therapy","volume":"2","author":"Mukhopadhyay","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2025.189459_bb0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev-pathmechdis-051821-114223","article-title":"Extrachromosomal DNA: An emerging Hallmark in human Cancer","volume":"17","author":"Wu","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0020","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1002\/jcp.30276","article-title":"Signaling, metabolism, and cancer: An important relationship for therapeutic intervention","volume":"236","author":"Vaghari-Tabari","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/pharmaceutics13050653","article-title":"Targeting KRAS in solid tumors: current challenges and future opportunities of novel KRAS inhibitors","volume":"13","author":"Indini","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbcan.2025.189459_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0040","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2019.01.013","article-title":"KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK\/ERK pathway in pancreatic cancer","volume":"446","author":"Cheng","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189459_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","article-title":"The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity","volume":"470","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189459_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.850856","article-title":"The give-and-take interaction between the tumor microenvironment and immune cells regulating tumor progression and repression","volume":"13","author":"Pernot","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12943-024-01981-5","article-title":"Cancer immunometabolism: advent, challenges, and perspective","volume":"23","author":"Dang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-024-02216-3","article-title":"Targeting KRAS: from metabolic regulation to cancer treatment","volume":"24","author":"Shi","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0070","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2025.189459_bb0075","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2025.189459_bb0080","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","article-title":"Targeting KRAS in cancer","volume":"30","author":"Singhal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0085","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF \u2014 a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0090","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","article-title":"Modulation of microenvironment acidity reverses Anergy in human and murine tumor-infiltrating T lymphocytes","volume":"72","author":"Calcinotto","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0095","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.3389\/fimmu.2019.01878","article-title":"Lactate induces pro-tumor reprogramming in Intratumoral Plasmacytoid dendritic cells","volume":"10","author":"Raychaudhuri","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0100","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, High-Lactate Environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0105","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell\u2013derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2025.189459_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2020.101055","article-title":"Lipids in the tumor microenvironment: from cancer progression to treatment","volume":"80","author":"Corn","year":"2020","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0115","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.3892\/or.2015.3805","article-title":"Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells","volume":"33","author":"Chen","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2025.189459_bb0120","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/s41467-022-29000-5","article-title":"Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb0125","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1158\/1538-7445.AM2015-734","article-title":"Abstract 734: synergistic antitumor effect of vemurafenib and metformin in thyroid cancer","volume":"75","author":"Hanly","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0130","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.cell.2024.02.044","volume":"187","author":"Five decades of advances in cancer research","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev-med-061512-105739","article-title":"Thyroid Cancer","volume":"65","author":"Carling","year":"2014","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0140","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.2174\/0929867328666211012093423","article-title":"Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors","volume":"29","author":"Xu","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189459_bb0145","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0150","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/jnci\/dji129","article-title":"Risk of thyroid Cancer after exposure to 131 I in childhood","volume":"97","author":"Cardis","year":"2005","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2025.189459_bb0155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid Cancer: A review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2025.189459_bb0160","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1056\/NEJMoa054022","article-title":"Effect of iodine intake on thyroid diseases in China","volume":"354","author":"Teng","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/965212","article-title":"Worldwide increasing incidence of thyroid Cancer: update on epidemiology and risk factors","volume":"2013","author":"Pellegriti","year":"2013","journal-title":"J Cancer Epidemiol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0170","first-page":"1457","article-title":"High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma","volume":"4","author":"Bongarzone","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189459_bb0175","first-page":"4459","article-title":"Activated ras oncogenes in human thyroid cancers","volume":"48","author":"Lemoine","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0180","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1089\/thy.2023.0045","article-title":"Progress in thyroid Cancer genomics: A 40-year journey","volume":"33","author":"Fagin","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.bbcan.2025.189459_bb0185","doi-asserted-by":"crossref","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant\u2013induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2025.189459_bb0190","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189459_bb0195","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/apm.13267","article-title":"Preoperative BRAFV600E mutation detection in thyroid carcinoma by immunocytochemistry","volume":"130","author":"Swan","year":"2022","journal-title":"APMIS"},{"key":"10.1016\/j.bbcan.2025.189459_bb0200","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0205","first-page":"15155","article-title":"Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer","volume":"8","author":"Ming","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.14740\/jocmr2480w","article-title":"Signaling pathways in thyroid Cancer and their therapeutic implications","volume":"8","author":"Jin","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101013","article-title":"Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance","volume":"72","author":"Shen","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bbcan.2025.189459_bb0220","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41467-024-47581-1","article-title":"Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks","volume":"15","author":"Qu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb0225","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid Cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0230","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0235","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 trial of Selpercatinib in advanced RET -mutant medullary thyroid Cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0240","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion\u2013positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0245","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.mce.2009.10.013","article-title":"The role of the PAX8\/PPAR\u03b3 fusion oncogene in the pathogenesis of follicular thyroid cancer","volume":"321","author":"Eberhardt","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0250","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrendo.2014.115","article-title":"Pax-8\u2013PPAR-\u03b3 fusion protein in thyroid carcinoma","volume":"10","author":"Raman","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0255","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144847","article-title":"NTRK and RET fusion\u2013directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","volume":"131","author":"Lee","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189459_bb0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41698-023-00449-x","article-title":"ALK fusions in the pan-cancer setting: another tumor-agnostic target?","volume":"7","author":"Shreenivas","year":"2023","journal-title":"Npj Precis Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0265","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.3390\/ijms25126734","article-title":"Antineoplastic effect of ALK inhibitor Crizotinib in primary human anaplastic thyroid Cancer cells with STRN\u2013ALK fusion in vitro","volume":"25","author":"Ferrari","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189459_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115193","article-title":"Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN \u2013 ALK fusion","volume":"216","author":"Buriolla","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0275","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0280","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"The Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189459_bb0285","article-title":"Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2025.189459_bb0290","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","article-title":"Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targeting in thyroid Cancer","volume":"109","author":"Zhang","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0295","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1089\/thy.2013.0235","article-title":"Concomitant BRAFV600E mutation and RET\/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma","volume":"24","author":"Guerra","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb0305","first-page":"53","article-title":"Molecular pathology of differentiated thyroid cancer","author":"A G, Mg B, C M, D D, Ma P","year":"2009","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbcan.2025.189459_bb0310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","article-title":"Integrated proteogenomic characterization of medullary thyroid carcinoma","volume":"8","author":"Shi","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.bbcan.2025.189459_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/4915736","article-title":"Prognostic impact of miR-224 and RAS mutations in medullary thyroid carcinoma","volume":"2017","author":"Cavedon","year":"2017","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.218","article-title":"Metabolic reprogramming in cancer: mechanisms and therapeutics","volume":"4","author":"Nong","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2025.189459_bb0325","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1158\/1535-7163.MCT-16-0068","article-title":"The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate\u2013Lactate Exchange in BRAF-Mutant Human Melanoma Cells","volume":"15","author":"Delgado-Goni","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb0330","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/pcmr.12742","article-title":"Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer","volume":"32","author":"Theodosakis","year":"2019","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0335","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41416-023-02282-2","article-title":"Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1\u03b1-mediated glycolytic phenotype","volume":"129","author":"Aprile","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0350","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/febs.14786","article-title":"Mitochondrial metabolism is inhibited by the HIF 1\u03b1- MYC - PGC -1\u03b2 axis in BRAF V600E thyroid cancer","volume":"286","author":"Gao","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.bbcan.2025.189459_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb0410","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1089\/thy.2020.0311","article-title":"Fine-tuning lipid metabolism by targeting mitochondria-associated acetyl-CoA-carboxylase 2 in BRAFV600E papillary thyroid carcinoma","volume":"31","author":"Valvo","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb0550","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41419-023-06041-2","article-title":"Co-inhibition of glutaminolysis and one-carbon metabolism promotes ROS accumulation leading to enhancement of chemotherapeutic efficacy in anaplastic thyroid cancer","volume":"14","author":"Hwang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189459_bb0555","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0560","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1089\/thy.2023.0700","article-title":"BRAFV600E\/p-ERK\/p-DRP1(Ser616) promotes tumor progression and reprogramming of glucose metabolism in papillary thyroid Cancer","volume":"34","author":"Wen","year":"2024","journal-title":"Thyroid Off J Am Thyroid Assoc."},{"key":"10.1016\/j.bbcan.2025.189459_bb0495","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/onc.2015.179","article-title":"Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP","volume":"35","author":"Ricoult","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189459_bb0565","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1186\/s12885-021-08499-9","article-title":"Pyruvate carboxylase promotes thyroid cancer aggressiveness through fatty acid synthesis","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0570","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-14-2425","article-title":"Metabolic dependencies in RAS -driven cancers","volume":"21","author":"Kimmelman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0530","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1210\/jc.2014-3023","article-title":"Iodide- and glucose-handling gene expression regulated by Sorafenib or Cabozantinib in papillary thyroid Cancer","volume":"100","author":"Ruan","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0545","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3892\/ijo.2022.5399","article-title":"GDNF regulates lipid metabolism and glioma growth through RET\/ERK\/HIF-1\/SREBP-1","volume":"61","author":"Yu","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0575","doi-asserted-by":"crossref","first-page":"19274","DOI":"10.1074\/jbc.M116.740324","article-title":"Adipogenic differentiation of thyroid Cancer cells through the Pax8-PPAR\u03b3 fusion protein is regulated by thyroid transcription factor 1 (TTF-1)","volume":"291","author":"Xu","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2025.189459_bb0580","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.010","article-title":"The complexity of p53-mediated metabolic regulation in tumor suppression","volume":"85","author":"Liu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0585","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.18632\/oncotarget.380","article-title":"Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors","volume":"2","author":"Arciuch","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189459_bb0590","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12022-015-9388-1","article-title":"Mutations of TSHR and TP53 genes in an aggressive clear cell follicular carcinoma of the thyroid","volume":"26","author":"Tong","year":"2015","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0595","doi-asserted-by":"crossref","first-page":"eadg7125","DOI":"10.1126\/sciadv.adg7125","article-title":"TERT accelerates BRAF mutant\u2013induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis","volume":"9","author":"Yu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2025.189459_bb0600","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/neuonc\/noab093","article-title":"Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas","volume":"23","author":"Viswanath","year":"2021","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.bbcan.2025.189459_bb0340","article-title":"Exploring the diverse role of pyruvate kinase M2 in cancer: navigating beyond glycolysis and the Warburg effect","volume":"1879","author":"Upadhyay","year":"2024","journal-title":"Biochim Biophys Acta BBA - Rev Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit Cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbcan.2025.189459_bb0300","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0355","first-page":"1052","article-title":"BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer","volume":"23","author":"Zerilli","year":"2010","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc."},{"key":"10.1016\/j.bbcan.2025.189459_bb0370","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201606","article-title":"Lipid metabolism and cancer","volume":"218","author":"Bian","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0375","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ijc.24760","article-title":"In vivo evidence of duality effects for lovastatin in a nude mouse cancer model","volume":"126","author":"Wang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0380","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12943-025-02263-4","article-title":"Reprogramming of thyroid Cancer metabolism: from mechanism to therapeutic strategy","volume":"24","author":"Wan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0385","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.gde.2008.02.003","article-title":"Brick by brick: metabolism and tumor cell growth","volume":"18","author":"DeBerardinis","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbcan.2025.189459_bb0390","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1038\/s41467-018-04664-0","article-title":"Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy","volume":"9","author":"Talebi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb0395","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-022-19459-z","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O\u2019Farrell","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189459_bb0400","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4155\/fmc-2019-0312","article-title":"Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs","volume":"12","author":"Wu","year":"2020","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189459_bb0405","article-title":"Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer","volume":"1878","author":"He","year":"2023","journal-title":"Biochim Biophys Acta BBA - Rev Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb0415","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Gago S, Vicente-Guti\u00e9rrez J, Ruiz-Rodr\u00edguez JM, Calafell J, \u00c1lvarez-\u00c1lvarez A, Lasa M, et al. Autophagy sustains mitochondrial respiration and determines resistance to BRAFV600E inhibition in thyroid carcinoma cells. Autophagy. 20:1383\u20131397.","DOI":"10.1080\/15548627.2024.2312790"},{"key":"10.1016\/j.bbcan.2025.189459_bb0420","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1210\/jc.2004-1394","article-title":"Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas","volume":"90","author":"Porra","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.737127","article-title":"Multi-omics analysis of fatty acid metabolism in thyroid carcinoma","volume":"11","author":"Lu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0430","doi-asserted-by":"crossref","first-page":"E697","DOI":"10.1210\/jc.2014-2764","article-title":"Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals Stearoyl CoA desaturase 1 as a novel therapeutic target","volume":"100","author":"von Roemeling","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0435","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41416-019-0620-5","article-title":"New aspects of amino acid metabolism in cancer","volume":"122","author":"Vettore","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0440","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q\u2019s next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189459_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102795","article-title":"Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma","volume":"129","author":"Loftus","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2025.189459_bb0450","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41419-019-1850-4","article-title":"Long noncoding RNA ABHD11-AS1 functions AS a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p\/SLC1A5 axis","volume":"10","author":"Zhuang","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189459_bb0455","first-page":"167","article-title":"Expression of glutamine metabolism-related proteins in H\u00fcrthle cell neoplasm of thyroid: comparison with follicular neoplasm","volume":"34","year":"2018","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0460","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13046-018-0907-z","article-title":"The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model","volume":"37","author":"H\u00e4fliger","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0465","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/bjc.2014.88","article-title":"ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer","volume":"110","author":"Shimizu","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0470","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2265.1999.00704.x","article-title":"Prevalence of Ras mutations in thyroid neoplasia","volume":"50","author":"Esapa","year":"1999","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0475","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0480","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.molcel.2016.02.009","article-title":"Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis","volume":"61","author":"Li","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0485","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0490","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","article-title":"RAS mutations in thyroid Cancer","volume":"18","author":"Howell","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2025.189459_bb0500","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1158\/0008-5472.CAN-22-2679","article-title":"Oncogenic KRASG12D reprograms lipid metabolism by upregulating SLC25A1 to drive pancreatic tumorigenesis","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbcan.2025.189459_bb0510","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3803\/EnM.2020.35.2.227","article-title":"Amino acid transporters as potential therapeutic targets in thyroid Cancer","volume":"35","author":"Enomoto","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0515","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202502714","article-title":"Mechanistic foundations of KRAS-driven tumor ecosystems: integrating crosstalk among immune, metabolic, microbial, and stromal microenvironment","volume":"12","author":"Ma","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2025.189459_bb0520","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s42255-020-00315-1","article-title":"KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth","volume":"2","author":"Raho","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0525","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189459_bb0535","first-page":"127","article-title":"18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131","volume":"34","author":"Feine","year":"1995","journal-title":"Nukl Nucl Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0540","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-08-2742","article-title":"Targeting the RET pathway in thyroid Cancer","volume":"15","author":"Wells","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0605","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of Cancer Immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0650","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1089\/thy.2014.0134","article-title":"BRAFV600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration","volume":"24","author":"Angell","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb0750","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-020-01818-1","article-title":"PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2\/Ras\/MAPK signalling in thyroid cancer cells","volume":"40","author":"Liotti","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0615","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153470","article-title":"Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47","volume":"133","author":"Hu","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189459_bb0635","doi-asserted-by":"crossref","first-page":"1171816","DOI":"10.3389\/fimmu.2023.1171816","article-title":"\u03b2-Catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in BrafV600E-driven thyroid cancer cells","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0780","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mco2.10","article-title":"Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS","volume":"1","author":"Ward","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.bbcan.2025.189459_bb0785","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1038\/sj.onc.1206759","article-title":"Tyrosine kinase oncoprotein, RET\/PTC3, induces the secretion of myeloid growth and chemotactic factors","volume":"22","author":"Russell","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2025.189459_bb0790","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12902-024-01586-5","article-title":"Next-generation sequencing identified that RET variation associates with lymph node metastasis and the immune microenvironment in thyroid papillary carcinoma","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.bbcan.2025.189459_bb0795","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2265.2009.03699.x","article-title":"The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies","volume":"72","author":"Muzza","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0800","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.18632\/oncotarget.14050","article-title":"Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer","volume":"8","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189459_bb0805","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/1947601910373545","article-title":"Expression of the PAX8\/PPAR\u03b3 fusion protein is associated with decreased neovascularization in vivo","volume":"1","author":"Reddi","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0810","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/cancers16173069","article-title":"TP53 mutation-mediated immune evasion in Cancer: mechanisms and therapeutic implications","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189459_bb0815","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1002\/cam4.3376","article-title":"TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0820","doi-asserted-by":"crossref","first-page":"1440722","DOI":"10.3389\/fendo.2024.1440722","article-title":"BRAFV600E\/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression","volume":"15","author":"Sigarteu Chindris","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0610","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s00262-024-03879-z","article-title":"Navigating TAM receptor dynamics in tumour immunotherapy","volume":"74","author":"Yang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189459_bb0620","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.4251\/wjgo.v13.i12.2129","article-title":"BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs","volume":"13","author":"Zhi","year":"2021","journal-title":"World J Gastrointest Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0625","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4132\/jptm.2015.06.01","article-title":"Cancers with higher density of tumor-associated macrophages were associated with poor survival rates","volume":"49","author":"Jung","year":"2015","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0630","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00335-018-9781-4","article-title":"Roles of cytotoxic and helper innate lymphoid cells in cancer","volume":"29","author":"Guillerey","year":"2018","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.bbcan.2025.189459_bb0640","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41419-022-05510-4","article-title":"Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189459_bb0645","article-title":"T cell exhaustion in human cancers","volume":"1879","author":"Kang","year":"2024","journal-title":"Biochim Biophys Acta BBA - Rev Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb0655","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.3390\/ijms20184413","article-title":"Immune and inflammatory cells in thyroid Cancer microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189459_bb0660","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2025.189459_bb0665","first-page":"3421","article-title":"The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland","volume":"80","author":"Matsubayashi","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0670","article-title":"Decoding the role of FOXP3 in esophageal cancer: underlying mechanisms and therapeutic implications","volume":"1879","author":"Wang","year":"2024","journal-title":"Biochim Biophys Acta BBA - Rev Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb0675","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.04.005","article-title":"Tumor promoting role of anti-tumor macrophages in tumor microenvironment","volume":"316","author":"Goswami","year":"2017","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0685","article-title":"Single-cell transcriptome analysis reveals inter-tumor heterogeneity in bilateral papillary thyroid carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0690","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","article-title":"Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic Cancer","volume":"20","author":"Jang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189459_bb0695","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12020-012-9853-2","article-title":"Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter","volume":"44","author":"Yu","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.bbcan.2025.189459_bb0700","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/2326-6066.CIR-17-0655","article-title":"IL22 promotes Kras -mutant lung Cancer by induction of a Protumor immune response and protection of Stemness properties","volume":"6","author":"Khosravi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0705","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb0710","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1878-0261.12135","article-title":"Inhibition of IL-6-JAK\/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1\/NKG2D ligand levels","volume":"12","author":"Xu","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0715","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1479-5876-12-151","article-title":"Synergistic effects of IL-4 and TNF\u03b1 on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation","volume":"12","author":"Quandt","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0720","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031849","article-title":"Kras and tumor immunity: friend or foe?","volume":"8","author":"Cullis","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0725","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41392-023-01365-z","article-title":"Emerging phagocytosis checkpoints in cancer immunotherapy","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20507","article-title":"Don\u2019t eat me\/eat me signals as a novel strategy in cancer immunotherapy","volume":"9","author":"Khalaji","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bbcan.2025.189459_bb0735","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway. Longo DL, editor","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0740","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 blockade in anaplastic thyroid carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0745","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","article-title":"Oncogenic RAS signaling promotes tumor Immunoresistance by stabilizing PD-L1 mRNA","volume":"47","author":"Coelho","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2025.189459_bb0755","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0760","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2025.189459_bb0765","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189459_bb0770","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/ERC-17-0532","article-title":"Immune landscape of papillary thyroid cancer and immunotherapeutic implications","volume":"25","author":"Na","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0775","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009128","volume":"12","author":"Chae","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0825","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of Cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0830","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.celrep.2017.07.054","article-title":"Pharmacologic or genetic targeting of glutamine Synthetase skews macrophages toward an M1-like phenotype and inhibits tumor metastasis","volume":"20","author":"Palmieri","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189459_bb0835","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/s41467-018-04719-2","article-title":"Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice","volume":"9","author":"Loftus","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb0840","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1530\/ERC-11-0360","article-title":"Oxidative stress: a new risk factor for thyroid cancer","volume":"19","author":"Xing","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0845","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","article-title":"Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy","volume":"16","author":"Yang","year":"2023","journal-title":"J. Hematol. OncolJ Hematol Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113702","article-title":"Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer","volume":"144","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0855","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317695922","article-title":"Glycolysis-related protein expression in thyroid cancer","volume":"39","author":"Nahm","year":"2017","journal-title":"Tumour Biol J Int Soc Oncodevelopmental Biol Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0860","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/RLU.0b013e3182393599","article-title":"Glucose transporter 1 expression, tumor proliferation, and iodine\/glucose uptake in thyroid Cancer with emphasis on poorly differentiated thyroid carcinoma","volume":"37","author":"Grabellus","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb0865","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1089\/thy.2009.0195","article-title":"Potential utility and limitations of thyroid Cancer cell lines as models for studying thyroid Cancer","volume":"19","author":"Pilli","year":"2009","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb0870","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929091","article-title":"What is the status of immunotherapy in thyroid neoplasms?","volume":"13","author":"Garcia-Alvarez","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0875","article-title":"A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2025.189459_bb0880","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ccell.2021.05.010","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb0885","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221101691","article-title":"RET kinase inhibitors for RET -altered thyroid cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0890","article-title":"Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities","volume":"1878","author":"Zhang","year":"2023","journal-title":"Biochim Biophys Acta BBA - Rev Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb0895","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","article-title":"The dormant cancer cell life cycle","volume":"20","author":"Phan","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0900","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2014.07.010","article-title":"Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors","volume":"8","author":"Sos","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2025.189459_bb0905","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb0910","doi-asserted-by":"crossref","first-page":"227","DOI":"10.21147\/j.issn.1000-9604.2025.02.09","article-title":"Reprogramming of fatty acid metabolism in thyroid cancer: potential targets and mechanisms","volume":"37","author":"Ping","year":"2025","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb0915","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s12672-025-02853-0","article-title":"Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0920","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to Sorafenib","volume":"150","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbcan.2025.189459_bb0925","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3803\/EnM.2023.1802","article-title":"Metabolic reprogramming in thyroid Cancer","volume":"39","author":"Ju","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0930","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189459_bb0935","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"V600E BRAF is associated with disabled feedback inhibition of RAF\u2013MEK signaling and elevated transcriptional output of the pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbcan.2025.189459_bb0940","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/15384047.2018.1480289","article-title":"Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations","volume":"19","author":"Ofir Dovrat","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb0945","article-title":"Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors","volume":"6","author":"Levy","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.bbcan.2025.189459_bb0950","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1210\/jc.2016-1999","article-title":"Targeting autophagy sensitizes BRAF-mutant thyroid Cancer to Vemurafenib","volume":"102","author":"Wang","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0955","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.molonc.2015.08.003","article-title":"Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells","volume":"10","author":"Baenke","year":"2016","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0960","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/JHC.S396231","article-title":"Potential treatment strategies for hepatocellular carcinoma cell sensitization to Sorafenib","volume":"10","author":"Jiang","year":"2023","journal-title":"J Hepatocell Carcinoma."},{"key":"10.1016\/j.bbcan.2025.189459_bb0965","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JME-16-0134","article-title":"Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo","volume":"58","author":"Shen","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0970","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0975","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism in tumor-targeting immunity","volume":"24","author":"Martino","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0995","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor Dabrafenib in patients with metastatic BRAF-mutant thyroid Cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb1005","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2025.189459_bb1250","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/1078-0432.CCR-11-0563","article-title":"Phase II efficacy and Pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 refractory papillary thyroid carcinoma with or without follicular elements","volume":"18","author":"Hayes","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb1085","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET -altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb1095","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41392-024-02006-9","article-title":"First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb1125","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4049\/jimmunol.2000137","article-title":"Metformin and 2-Deoxyglucose collaboratively suppress human CD4+ T cell effector functions and activation-induced metabolic reprogramming","volume":"205","author":"Tan","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1135","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3892\/ol.2015.3518","article-title":"Inflammatory mediators, tumor necrosis factor-\u03b1 and interferon-\u03b3, induce EMT in human PTC cell lines","volume":"10","author":"Lv","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2025.189459_bb1255","doi-asserted-by":"crossref","first-page":"737","DOI":"10.7150\/jca.28111","article-title":"Genistein inhibits human papillary thyroid cancer cell detachment, invasion and metastasis","volume":"10","author":"Zhang","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb1260","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s11427-019-1735-4","article-title":"Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy","volume":"64","author":"Fan","year":"2021","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bbcan.2025.189459_bb1150","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbrc.2016.08.101","article-title":"Atorvastatin and rosuvastatin improve physiological parameters and alleviate immune dysfunction in metabolic disorders","volume":"478","author":"Lee","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2025.189459_bb1155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1530\/JOE-10-0411","article-title":"Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells","volume":"210","author":"Zeybek","year":"2011","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1265","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bcp.2011.08.021","article-title":"Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the rho\/ROCK-mediated pathway","volume":"82","author":"Zhong","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1165","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s40618-023-02294-y","article-title":"Targeting glutamine metabolism exhibits anti-tumor effects in thyroid cancer","volume":"47","author":"Zhang","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bbcan.2025.189459_bb1270","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.cell.2018.10.001","article-title":"Distinct regulation of Th17 and Th1 cell differentiation by Glutaminase-dependent metabolism","volume":"175","author":"Johnson","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb1190","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb1205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/clinem\/dgaa656","article-title":"Inhibition of BRAF sensitizes thyroid carcinoma to immunotherapy by enhancing tsMHCII-mediated immune recognition","volume":"106","author":"Zhi","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb1210","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to Dabrafenib\/Trametinib for BRAFV600E -mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid\u00ae"},{"key":"10.1016\/j.bbcan.2025.189459_bb1275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with Vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb1220","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","article-title":"Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1","volume":"35","author":"Wu","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb0980","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-11-0129","article-title":"Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population","volume":"165","author":"Ahmed","year":"2011","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0985","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb0990","doi-asserted-by":"crossref","first-page":"36","DOI":"10.18632\/oncotarget.28544","article-title":"Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation","volume":"15","author":"Lee","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2025.189459_bb1000","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid Cancer with Dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb1010","first-page":"1334","article-title":"Dabrafenib versus Dabrafenib + Trametinib in BRAF -mutated radioactive iodine refractory differentiated thyroid Cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb1015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1020","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1016\/j.bmcl.2012.07.082","article-title":"Ras inhibition via direct Ras binding\u2014is there a path forward?","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bbcan.2025.189459_bb1025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb1030","first-page":"7","article-title":"Lenvatinib for anaplastic thyroid Cancer","author":"Tahara","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1035","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of Lenvatinib for the treatment of patients with anaplastic thyroid Cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"173","key":"10.1016\/j.bbcan.2025.189459_bb1040","first-page":"210","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","volume":"2022","author":"Higashiyama","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.bbcan.2025.189459_bb1050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb1055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12020-017-1233-5","article-title":"Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes","volume":"56","author":"Haddad","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.bbcan.2025.189459_bb1060","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid Cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1065","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid Cancer: A randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1075","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/DDDT.S72495","article-title":"Selective use of vandetanib in the treatment of thyroid cancer","author":"Antonelli","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb1080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/thy.2022.0027","article-title":"A randomized, double-blind noninferiority study to evaluate the efficacy of the Cabozantinib tablet at 60 mg per day compared with the Cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer","volume":"32","author":"Capdevila","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.bbcan.2025.189459_bb1100","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.ccell.2020.04.005","article-title":"Dietary approaches to Cancer therapy","volume":"37","author":"Tajan","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2025.189459_bb1105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18632\/aging.101382","article-title":"Ketogenic diet in cancer therapy","volume":"10","author":"Weber","year":"2018","journal-title":"Aging"},{"key":"10.1016\/j.bbcan.2025.189459_bb1110","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41419-023-06348-0","article-title":"Fasting regulates mitochondrial function through lncRNA PRKCQ-AS1-mediated IGF2BPs in papillary thyroid carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2025.189459_bb1115","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cmet.2016.12.010","article-title":"Prevention of dietary-fat-fueled Ketogenesis attenuates BRAF V600E tumor growth","volume":"25","author":"Xia","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb1120","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.3390\/cancers14194568","article-title":"Targeting glucose metabolism enzymes in Cancer treatment: current and emerging strategies","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189459_bb1130","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216396","article-title":"Targeting cancer metabolic pathways for improving chemotherapy and immunotherapy","volume":"575","author":"Luo","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2025.189459_bb1140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2025.189459_bb1145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00109-009-0561-1","article-title":"Statins enhance peroxisome proliferator-activated receptor \u03b3 coactivator-1\u03b1 activity to regulate energy metabolism","volume":"88","author":"Wang","year":"2010","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb1160","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/jcpt.12491","article-title":"Exploring New Zealand prescription data using sequence symmetry analyses for predicting adverse drug reactions","volume":"42","author":"Nishtala","year":"2017","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb1170","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2025.189459_bb1175","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","article-title":"Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb1180","doi-asserted-by":"crossref","first-page":"ltab010","DOI":"10.1093\/immadv\/ltab010","article-title":"A glutamine \u2018tug-of-war\u2019: targets to manipulate glutamine metabolism for cancer immunotherapy","volume":"1","author":"Pallett","year":"2021","journal-title":"Immunother Adv."},{"key":"10.1016\/j.bbcan.2025.189459_bb1185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fimmu.2018.00353","article-title":"Targeting tumor metabolism: A new challenge to improve immunotherapy","volume":"9","author":"Kouidhi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1195","doi-asserted-by":"crossref","first-page":"1365055","DOI":"10.3389\/fonc.2024.1365055","article-title":"Research progress of immunotherapy against anaplastic thyroid cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1200","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.22.01693","article-title":"ANCHOR CRC: results from a single-arm, phase II study of Encorafenib plus Binimetinib and Cetuximab in previously untreated BRAFV600E -mutant metastatic colorectal Cancer","volume":"41","author":"Van Cutsem","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1215","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11684-023-1025-7","article-title":"Metabolic interventions combined with CTLA-4 and PD-1\/PD-L1 blockade for the treatment of tumors: mechanisms and strategies","volume":"17","author":"Liao","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb1225","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/0008-5472.CAN-15-1743","article-title":"Neutralization of tumor acidity improves antitumor responses to immunotherapy","volume":"76","author":"Pilon-Thomas","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb1230","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-23-0966","article-title":"FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189459_bb1235","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/1535-7163.MCT-20-0430","article-title":"The glutaminase inhibitor CB-839 (Telaglenastat) enhances the anti-melanoma activity of T cell mediated immunotherapies","volume":"20","author":"Varghese","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2025.189459_bb1240","first-page":"189","article-title":"Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma","volume":"2","author":"Wu","year":"2021","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2025.189459_bb1245","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cmet.2022.04.003","article-title":"Glutaminase inhibition impairs CD8 T cell activation in STK11\u2212\/Lkb1-deficient lung cancer","volume":"34","author":"Best","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2025.189459_bb1280","article-title":"A spatially resolved transcriptome landscape during thyroid cancer progression","volume":"6","author":"Liao","year":"2025","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.bbcan.2025.189459_bb1285","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0392","article-title":"Novel insights in advanced thyroid carcinoma: from mechanisms to treatments: development of 3D organoid models to study aggressive thyroid cancers","volume":"14","author":"Rios-Morris","year":"2025","journal-title":"Eur Thyroid J."},{"key":"10.1016\/j.bbcan.2025.189459_bb1290","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.trecan.2022.06.001","article-title":"Immune organoids: from tumor modeling to precision oncology","volume":"8","author":"Dao","year":"2022","journal-title":"Trends Cancer."},{"key":"10.1016\/j.bbcan.2025.189459_bb1295","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-022-01278-4","article-title":"Tumor organoids: applications in cancer modeling and potentials in precision medicine","volume":"15","author":"Xu","year":"2022","journal-title":"J. Hematol. OncolJ Hematol Oncol."},{"key":"10.1016\/j.bbcan.2025.189459_bb1300","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd3504","article-title":"Targeting cancer metabolism: a therapeutic window opens","volume":"10","author":"Vander Heiden","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189459_bb1305","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41592-021-01276-3","article-title":"SEAM is a spatial single nuclear metabolomics method for dissecting tissue microenvironment","volume":"18","author":"Yuan","year":"2021","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bbcan.2025.189459_bb1310","doi-asserted-by":"crossref","first-page":"14438","DOI":"10.1038\/s41598-019-51000-7","article-title":"Altered levels of circulating nuclear and mitochondrial DNA in patients with papillary thyroid Cancer","volume":"9","author":"Perdas","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2025.189459_bb1315","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fgene.2020.00449","article-title":"A panel of plasma Exosomal miRNAs as potential biomarkers for differential diagnosis of thyroid nodules","volume":"11","author":"Liang","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbcan.2025.189459_bb1320","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.omtn.2023.06.001","article-title":"Integrated multiomics analysis and machine learning refine molecular subtypes and prognosis for muscle-invasive urothelial cancer","volume":"33","author":"Chu","year":"2023","journal-title":"Mol Ther Nucleic Acids."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2500201X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2500201X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:39:01Z","timestamp":1781066341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X2500201X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":263,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0304419X2500201X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189459","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189459"}}